Peripheral Immune-Mediated Neuropathy Before and During the COVID-19 Pandemic: A Retrospective Cross-Sectional Study in a Referral Center
- PMID: 39712713
- PMCID: PMC11662227
- DOI: 10.7759/cureus.74131
Peripheral Immune-Mediated Neuropathy Before and During the COVID-19 Pandemic: A Retrospective Cross-Sectional Study in a Referral Center
Abstract
Background: There are currently seven coronaviruses that can infect humans and the latest addition to these viruses is the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Infection by SARS-CoV-2 is known commonly as coronavirus disease 2019 (COVID-19). Aside from common manifestations of cough and fever, neurologic symptoms such as headache, disturbed consciousness, paresthesia, and seizures have also been seen. By identifying the incidence of peripheral immune-mediated neuropathies (PIMN), early prevention can be made.
Methods: This cross-sectional retrospective analytic study reviewed the case records of patients examined at the Center for Neurodiagnostic and Therapeutic Services (CNS) of Metropolitan Medical Center from January 2018 to December 2021.
Results: The period incidence of Guillain-Barré Syndrome (GBS) for the years 2018-2019 and 2020-2021 were 9.21% and 24.44%, respectively. The obtained p-value was 0.0226, which was lower than the set p-value of 0.05. Therefore, the period incidence of GBS for 2020-2021 was significantly higher when compared to that of 2018-2019.
Conclusion: There has been an increase in cases of GBS during the COVID-19 pandemic.
Keywords: chronic inflammatory demyelinating polyradiculopathy; cidp; dm neuropathy; gbs; guillain-barre syndrome; peripheral immune-mediated neuropathy.
Copyright © 2024, Su et al.
Conflict of interest statement
Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. University of the East Ramon Magsaysay Memorial Medical Center, Inc., Research Institute for Health Sciences Ethics Review Committee issued approval 1263/E/2022/073. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
References
-
- SARS-CoV-2 can induce brain and spine demyelinating lesions. Zanin L, Saraceno G, Panciani PP, Renisi G, Signorini L, Migliorati K, Fontanella MM. https://doi.org/10.1007/s00701-020-04374-x. Acta Neurochir (Wien) 2020;162:1491–1494. - PMC - PubMed
-
- Case report: nerimyelitis optica associated with SARS-COV-2. Zhuang TY, Miskin D. https://practicalneurology.com/articles/2020-oct/case-report-neuromyelit... Pract Neurol. 2020:49–52.
LinkOut - more resources
Full Text Sources
Miscellaneous